EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Carbapenem-based versus non-carbapenem therapy for hospital-acquired and ventilator-associated pneumonia in a resource-limited setting: a retrospective cohort study of clinical outcomes

Uroosa Kanwal, Iyad Naeem Muhammad, Ale Zehra, Syed Shaukat Ali Muttaqi Shah, Falak Abro, Tehreem Ansari, Najia Rahim, Rabya Munawar, Mujahid Hussain

Journal of Pharmacy & Pharmaceutical Sciences · 2026

DOI: 10.3389/jpps.2026.17336 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2026. Verfasst von Uroosa Kanwal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan. Hauptthemen laut MEDLINE: Pneumonia, Ventilator-Associated, Carbapenems, Anti-Bacterial Agents, Healthcare-Associated Pneumonia. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are major causes of in-hospital mortality and antimicrobial resistance (AMR), particularly in low- and middle-income countries (LMICs). Carbapenems are commonly used due to their broad-spectrum activity; however, their efficacy in real-world clinical practices comparing carbapenem with non-carbapenem regimens in these settings is limited.

Objectives

To compare clinical outcomes between patients receiving carbapenem-based and non-carbapenem therapy for HAP and VAP at a tertiary care hospital in Pakistan.

Methods

This retrospective cohort study included 93 adult patients (HAP: n = 62, VAP: n = 31) over the period of 1 year. Demographics, comorbidities, microbial isolates, treatment regimen, and clinical outcomes were analyzed using descriptive statistics, chi-square tests, and risk ratio calculations with 95% confidence interval. Multivariable logistic regression was planned to adjust for confounders but was not feasible due to missing severity score and biomarker data.

Results

HAP was more common in females (63%), while VAP showed a male predominance (52%). The most common pathogens were Acinetobacter spp. (HAP: 11.3%; VAP: 19.4%) and Pseudomonas aeruginosa (HAP: 11.3%; VAP: 16.1%). The most prevalent comorbidity in HAP was diabetes mellitus (38.7%). Carbapenem-based therapy (meropenem) was used in 65.6% of cases and the most frequently prescribed non-carbapenem agents were piperacillin-tazobactam, ceftazidime, and colistin. No significant difference in mortality was observed between carbapenem and non-carbapenem therapy in HAP (31.6% vs. 29.2%; RR 1.08, 95% CI 0.50–2.36, p = 0.840) or VAP (65.2% vs. 50.0%; RR 1.30, 95% CI 0.61–2.77, p = 0.440). VAP was associated with significantly higher crude mortality than HAP (61.3% vs. 30.6%; p = 0.005). Crude mortality rates appeared highest among patients in the Acinetobacter baumannii group (70.4%) and Pseudomonas aeruginosa group (31.3%), though treatment group difference were not statistically significant.

Conclusion

In this single-center retrospective cohort, no statistically significant association between carbapenem-based therapy and all-cause in-hospital mortality was detected in HAP or VAP. Crude mortality appeared highest among patients with Acinetobacter and Pseudomonas isolates. However, wide confidence intervals, treatment-selection bias, and unadjusted analyses preclude definitive conclusions. These findings should be considered hypothesis-generating, requiring confirmation in adequately powered, larger prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumonia, Ventilator-AssociatedCarbapenemsAnti-Bacterial AgentsHealthcare-Associated PneumoniaHumansRetrospective StudiesFemaleMaleMiddle AgedAdultResource-Limited SettingsCohort StudiesTreatment Outcome

Stichwörter der Autor:innen

antimicrobial stewardshipcarbapenem combination therapycarbapenem monotherapycarbapenem-based therapyhospital-acquired pneumonia (HAP)pathogen-specific mortalityventilator-acquired pneumonia (VAP)

Substanzen

CarbapenemsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan.
  • Department of Pharmacy Practice, Faculty of Pharmacy, Salim Habib University, Karachi, Pakistan.
  • Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Clinical Pharmacy, College of Pharmacy, Al-Farahidi University, Baghdad, Iraq.
  • Department of Pediatrics, Liaquat National Hospital, Karachi, Pakistan.
  • Department of Infectious Diseases, Dow University Hospital, Dow University of Health Sciences, Karachi, Pakistan.

Zitieren

APA

Kanwal, U., Muhammad, I. N., Zehra, A., Shah, S. S. A. M., Abro, F., Ansari, T., Rahim, N., Munawar, R., & Hussain, M. (2026). Carbapenem-based versus non-carbapenem therapy for hospital-acquired and ventilator-associated pneumonia in a resource-limited setting: a retrospective cohort study of clinical outcomes. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2026.17336

Vancouver

Kanwal U, Muhammad IN, Zehra A, Shah SSAM, Abro F, Ansari T, et al. Carbapenem-based versus non-carbapenem therapy for hospital-acquired and ventilator-associated pneumonia in a resource-limited setting: a retrospective cohort study of clinical outcomes. Journal of Pharmacy & Pharmaceutical Sciences. 2026. doi:10.3389/jpps.2026.17336

BibTeX
@article{Kanwal2026,
  author = {Kanwal, Uroosa and Muhammad, Iyad Naeem and Zehra, Ale and Shah, Syed Shaukat Ali Muttaqi and Abro, Falak and Ansari, Tehreem and Rahim, Najia and Munawar, Rabya and Hussain, Mujahid},
  title = {Carbapenem-based versus non-carbapenem therapy for hospital-acquired and ventilator-associated pneumonia in a resource-limited setting: a retrospective cohort study of clinical outcomes},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2026},
  doi = {10.3389/jpps.2026.17336}
}
Kostenlos starten →